Maarten L. Janmaat
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity.
Journal: EBioMedicine
Published: December 12, 2022
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models.
Journal: Life science alliance
Published: April 13, 2022
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Journal: Cancer research
Published: February 05, 2020
Bispecific antibodies: a mechanistic review of the pipeline.
Journal: Nature reviews. Drug discovery
Published: June 09, 2019
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
Journal: JCI insight
Published: February 25, 2019
Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.
Journal: Scientific reports
Published: September 20, 2016
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
Journal: Immunological reviews
Published: February 12, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026